SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
14 3월 2024 - 9:49PM
SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty
clinical-stage pharmaceutical company focusing on the development
of therapies to treat disorders and rare diseases of the central
nervous system, today announced that it has successfully dosed the
first patient in its SCI-210 clinical trial at the Soroka Medical
Center for pediatric patients who have Autism Spectrum Disorder
("ASD"). This significant milestone follows the Company's recent
announcement about the successful delivery of its innovative
SCI-210 treatment to the clinical trial site, enabling the
commencement of dosing.
SciSparc's proprietary SCI-210 treatment combines
cannabidiol-rich oil (“CBD”) and CannAmide™, SciSparc’s proprietary
palmitoylethanolamide-based tablets. The dosing of the first
patient signifies the transition from preparatory phases to active
treatment evaluation in the quest to offer a more effective and
safe treatment option for ASD.
"Dosing the first patient is always an
exciting moment in any clinical trial. As we work to offer new hope
to the patients, family members, and caretakers who are battling
this disorder, we are excited to kick-off this next phase of
development for SCI-210,” said Oz Adler, SciSparc's Chief Executive
Officer. "We are thrilled to reach this milestone, which brings us
one step closer to potentially offering a new beacon of hope for
patients and families affected by ASD. We are grateful to the
patients, Professor Meiri and his team involved in the clinical
trial. This achievement represents a pivotal moment for SciSparc as
we introduce SCI-210, an innovative cannabinoid-based
treatment."
The clinical trial aims to rigorously
evaluate the safety, tolerability, and efficacy of SCI-210 in
comparison to CBD monotherapy for the treatment of ASD. Designed as
a randomized, double-blind, placebo-controlled clinical trial with
cross-over, the study will span 20 weeks and enroll 60 children.
The trial's primary efficacy endpoints include three rigorous
assessments: the Aberrant Behavior Checklist-Community (ABC-C)
parent questionnaire; the Clinical Global Impressions-Improvement
(CGI-I) scale administered by healthcare professionals; and the
determination of the effective therapeutic dosage.
About SciSparc Ltd. (Nasdaq:
SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and
scientists. SciSparc’s focus is on creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the Company is currently engaged
in the following drug development programs based on THC and/or
non-psychoactive CBD: SCI-110 for the treatment of Tourette
Syndrome, for the treatment of Alzheimer's disease and agitation;
SCI-160 for the treatment of pain; and SCI- 210 for the treatment
of ASD and status epilepticus. The Company also owns a controlling
interest in a subsidiary whose business focuses on the sale of hemp
seeds oil-based products on the Amazon.com Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, SciSparc is using forward-looking
statements when it discusses the aims of the SCI-210 clinical
trial. Because such statements deal with future events and are
based on SciSparc's current expectations, they are subject to
various risks and uncertainties and actual results, performance or
achievements of SciSparc could differ materially from those
described in or implied by the statements in this press release.
The forward-looking statements contained or implied in this press
release are subject to other risks and uncertainties, including
those discussed under the heading "Risk Factors" in SciSparc's
Annual Report on Form 20-F filed with the SEC on May 1, 2023,
and in subsequent filings with the U.S. Securities and Exchange
Commission. Except as otherwise required by law, SciSparc disclaims
any intention or obligation to update or revise any forward-looking
statements, which speak only as of the date they were made, whether
as a result of new information, future events or circumstances or
otherwise.
Investor Contact:IR@scisparc.comTel: +972-3-6167055
SciSparc (NASDAQ:SPRC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
SciSparc (NASDAQ:SPRC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024